Enliven Therapeutics has finalized the design of its ENABLE-2 Phase 3 trial for relcobatinib, a drug targeting chronic myeloid leukemia (CML). The trial will compare relcobatinib to second-generation treatments in about 450 patients previously treated with tyrosine kinase inhibitors. The primary goal is to improve major molecular response rates at 24 weeks, aiming for at least a 10% improvement over current therapies. Enliven plans to begin the trial before the end of 2026, moving closer to potentially offering a best-in-class treatment for CML.
Enliven Therapeutics' recent FDA alignment on its ENABLE-2 Phase 3 trial design for relcobatinib provides context for healthcare sector activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 07, 2026 03:04 WIB: out of 100 priced US health-sector stocks, 47 rose and 53 fell. Notable movers include MESO at USD 13.58 with a 1-day change of -4.50% and a typical hold time of 14 days, CLPT at USD 11.01 down 4.43% with 79% buy order activity and a 9-day hold, and HUM at USD 404.74 up 4.22% with a typical hold time of 53 days but 100% sell order activity.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
